vartumab ADC-DXd

Vartumab ADC-DXd is a preclinical antibody-drug conjugate (ADC) designed to target oncofetal chondroitin sulfate (ofCS), a pan-cancer glycosaminoglycan modification found on tumor cells, in the malignant extracellular matrix, and on cancer-associated fibroblasts. The construct utilizes Vartumab, a monovalent single-chain variable fragment (scFv) fused to an albumin-binding domain for half-life extension, conjugated to the topoisomerase I inhibitor payload deruxtecan (DXd). It employs a cathepsin-cleavable glycine-glycine-phenylalanine-glycine (ggfg) tetrapeptide linker, which facilitates a potent bystander effect, allowing the cytotoxic payload to eliminate neighboring antigen-negative cells and supportive stromal cells within the dense tumor microenvironment. This dual targeting of malignant cells and the tumor-supportive stroma aims to provide more complete and lasting tumor regression across a broad range of solid malignancies.

Other names

Vartumab-DXdVartumab-ggfg-DXd